Pasireotide LAR
ApprovedPeptide
NovartisPasireotide LAR is one of 167 small molecule programs targeting Hepatic cysts. It is currently in Approved.
7
Indications
21
Total Trials
0
Active Trials
166
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
221 competitors in Liver Disease
#DrugCompanyPhaseTrials
1Pasireotide LAR
NovartisApproved
Mounjaro
Eli LillyPhase 3
Inderal
WWyeth-Lederle Vaccines
Phase 3
Viagra
VViatris Specialty LLC
Phase 3
Neurontin
VViatris Specialty LLC
Phase 3
Sandostatin
Sun PharmaPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Promacta
GSKPhase 2
Retatrutide
Eli LillyPhase 3
Virazole
CConrado Roberto Hoffmann Filho
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acromegaly4 trials
Show 1 more trial
Efficacy and Safety2 trials
Adenoma2 trials
11 more indications
Cushing's Disease1 trial
Merkel Cell Carcinoma1 trial
Statin1 trial
Metastatic1 trial
Trial1 trial
Treatment1 trial
Neuroendocrine Tumors1 trial
Hyperglycemia1 trial
Pituitary Tumor1 trial
Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
Terminated·—·Phase 2·NCT02749227·4 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pasireotide LAR. EMBL-EBI & Wellcome Sanger Institute.
- [4]